Corcept Therapeutics Incorporated

Company Overview

Business Model: Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on the discovery and development of medications that modulate the hormone cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The Company currently markets Korlym (mifepristone) 300 mg Tablets and an authorized generic version of Korlym in the United States for the treatment of hyperglycemia secondary to hypercortisolism (Cushing's syndrome) in adult patients with type 2 diabetes mellitus or glucose intolerance who have failed surgery or are not candidates for surgery. Corcept Therapeutics Incorporated has discovered over 1,000 proprietary selective cortisol modulators that bind to the glucocorticoid receptor (GR) without affinity for the progesterone receptor (PR), aiming to avoid PR-related adverse effects. These compounds are being evaluated in clinical trials for various serious disorders.

Market Position: Corcept Therapeutics Incorporated operates in the market for hypercortisolism treatments, where its Products compete with established therapies including surgery, radiation, and FDA-approved medications such as Signifor (pasireotide) and Isturisa (osilodrostat) from Recordati S.p.A., and Recorlev (levoketoconazole) from Xeris Biopharma Holdings, Inc. Additionally, off-label use of generic medications like ketoconazole and metyrapone presents competition. Teva Pharmaceuticals USA, Inc. launched a generic version of Korlym in January 2024, and Corcept Therapeutics Incorporated made its own authorized generic version available in June 2024. The Company's clinical studies, such as the CATALYST study, have identified a significant prevalence of hypercortisolism in patients with difficult-to-control diabetes (23.8% of 1,057 patients), indicating a substantial undiagnosed or inadequately treated patient population. Relacorilant has received Orphan Drug designation from the FDA and the European Commission for hypercortisolism, ovarian, and pancreatic cancers. Dazucorilant has received Fast Track Designation and orphan drug status from the FDA for the treatment of amyotrophic lateral sclerosis.

Recent Strategic Developments:

• Product Launches & Availability: In June 2024, Corcept Therapeutics Incorporated made an authorized generic version of Korlym available.
• Distribution Channel Transition: In June 2025, Corcept Therapeutics Incorporated notified Optime Care, Inc. that it would cease to be the exclusive specialty pharmacy provider, and in October 2025, delivered a termination notice effective January 8, 2026. Substantially all specialty pharmacy services were transferred to Curant Health Georgia, LLC in the fourth quarter of 2025, with Optime Care, Inc. ceasing services after the first quarter of 2026.
• Relacorilant for Hypercortisolism: In December 2024, Corcept Therapeutics Incorporated submitted a New Drug Application (NDA) to the FDA for relacorilant as a treatment for endogenous hypercortisolism. On December 30, 2025, the FDA issued a Complete Response Letter, declining approval and requesting additional evidence of efficacy. Corcept Therapeutics Incorporated is working with the FDA to determine the optimal path to approval.
• Relacorilant for Oncology: In July 2025, an NDA was submitted to the FDA for relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, accepted for filing in September 2025 with a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026. In October 2025, a marketing authorization application (MAA) was submitted to the European Medicines Agency for the same indication.
• Oncology Pipeline Expansion:
  • April 2025: Initiated Phase 2 BELLA trial for platinum-resistant ovarian cancer (Part A completed enrollment of 95 patients in December 2025), platinum-sensitive ovarian cancer, and endometrial cancer.
  • December 2025: Initiated Phase 2 TRIDENT trial for pancreatic cancer (planned enrollment of 50 patients).
  • First Quarter 2026: Will initiate Phase 2 STELLA trial for cervical cancer (planned enrollment of 50 patients) in collaboration with ARCAGY-GINECO.
• Nenocorilant for Oncology: In December 2025, initiated a Phase 1b SYNERGY trial for nenocorilant plus nivolumab in 30 patients with solid tumors.
• Miricorilant for Metabolic Diseases: Enrollment completed in both cohorts of the Phase 2b MONARCH trial for miricorilant in patients with metabolic dysfunction-associated steatohepatitis (MASH).
• Dazucorilant for ALS: Following Phase 2 DAZALS trial results showing a statistically significant reduction in early death, Corcept Therapeutics Incorporated is conducting a dose titration study and expects to start a pivotal Phase 3 trial in 2026.
• Office Space Expansion: In December 2025, exercised an expansion option for an additional 40,884 square feet of office space in Redwood City, California, commencing in the first quarter of 2026.
• Regulatory Impact: The One Big Beautiful Bill Act, enacted July 4, 2025, reduced funding to federal healthcare programs and imposed additional eligibility requirements, which may impact patient access and increase costs for Corcept Therapeutics Incorporated's financial assistance programs.

Geographic Footprint: Corcept Therapeutics Incorporated's commercial operations for Korlym and its authorized generic are primarily in the United States. The Company has wholly-owned subsidiaries in the United Kingdom (incorporated March 2017), the Netherlands (incorporated May 2025), and Switzerland (incorporated October 2025). Clinical trials and regulatory submissions for product candidates, such as relacorilant, target both the United States and the European Union. The Company's headquarters are located in Redwood City, California.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 98.3%
• Operating Margin: 5.9%
• Net Margin: 13.1%

Investment in Growth:

• R&D Expenditure: $254.9 million (33.5% of revenue)
• Capital Expenditures: $0.2 million
• Strategic Investments: Corcept Therapeutics Incorporated spent $172.9 million on share repurchases under its Stock Repurchase Program and $72.9 million to satisfy tax withholding requirements from stock option exercises and restricted stock vesting in 2025.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $172.9 million (2.6 million shares) under the Stock Repurchase Program in 2025. An additional $72.9 million was spent to satisfy tax withholding requirements from stock option exercises and restricted stock vesting. The Board of Directors authorized a $200 million stock repurchase program in January 2024.
• Dividend Payments: Corcept Therapeutics Incorporated has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.
• Future Capital Return Commitments: The $200 million Stock Repurchase Program, authorized in January 2024, may be modified, suspended, or discontinued at any time without notice.

Balance Sheet Position:

• Cash and Equivalents: $532.4 million (includes cash, cash equivalents, and marketable securities)
• Total Debt: Not explicitly disclosed as debt.
• Net Cash Position: $343.6 million (Total Cash, Cash Equivalents and Marketable Securities of $532.4 million minus Total Liabilities of $188.8 million)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not disclosed.

Cash Flow Generation:

• Operating Cash Flow: $142.0 million
• Free Cash Flow: $141.8 million (Operating Cash Flow of $142.0 million minus Capital Expenditures of $0.2 million)
• Cash Conversion Metrics: Not explicitly provided in the filing.

Operational Excellence

Production & Service Model: Corcept Therapeutics Incorporated relies on contract manufacturers for the production of its active pharmaceutical ingredient (API), tableting, and bottling of its Products and product candidates. The Company maintains significant quantities of API. Distribution and patient support services for its Products are managed through specialty pharmacy vendors. As of October 2025, Curant Health Georgia, LLC became the primary specialty pharmacy vendor, taking over from Optime Care, Inc. Corcept Therapeutics Incorporated's operational philosophy includes a commitment that no patient will be denied access to its Products for financial reasons, supported by patient assistance programs and donations to independent charitable foundations.

Supply Chain Architecture: Key Suppliers & Partners:

• API & Manufacturing: Contract manufacturers supply mifepristone (API for Korlym) and produce/bottle tablets.
• Specialty Pharmacy Services: Curant Health Georgia, LLC provides exclusive specialty pharmacy and patient support services for Corcept Therapeutics Incorporated's Products in the United States.
• Clinical Research Organizations (CROs): Syneos Health assists with ROSELLA and BELLA trials. Medpace Research assists with MOMENTUM and MONARCH trials.

Facility Network:

• Manufacturing: Relies on third-party contract manufacturing facilities.
• Research & Development: R&D activities are supported by internal personnel and external CROs.
• Distribution: Utilizes specialty pharmacy vendors for product distribution to patients.
• Corporate Facilities: Leases 50,632 square feet of office space in Redwood City, California, with an expansion option for an additional 40,884 square feet exercised in December 2025, commencing in Q1 2026.

Operational Metrics: Not explicitly provided in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Employs sales representatives to engage physicians caring for patients with hypercortisolism.
• Medical Science Liaisons: Maintains a field-based force of medical science liaisons.
• Specialty Pharmacy: Utilizes Curant Health Georgia, LLC as its specialty pharmacy vendor for dispensing Products and providing related patient support services.
• Physician & Patient Education: Develops and expands programs to educate physicians and patients on screening for hypercortisolism and the role of its Products.

Customer Portfolio: Enterprise Customers: Corcept Therapeutics Incorporated's Products are prescribed to patients with hypercortisolism.

• Customer Concentration: Receivables risk is diversified among various third-party payers, including pharmacy benefit managers, insurance companies, government programs, and private charities. No single customer concentration percentage is disclosed.

Geographic Revenue Distribution:

• United States: Primary market for Korlym and its authorized generic. No specific revenue breakdown by international region is provided.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The market for hypercortisolism treatments involves complex patient identification and management, as many patients are undiagnosed or inadequately treated. Cortisol modulation also shows promise in oncology, where cortisol activity can reduce chemotherapy efficacy, promote tumor growth, and suppress immune response. Metabolic dysfunction-associated steatohepatitis (MASH) is a significant cause of liver-related mortality, and amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular illness, representing areas of high unmet medical need that Corcept Therapeutics Incorporated is targeting.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Recordati S.p.A.: Markets Signifor (pasireotide) and Isturisa (osilodrostat) for Cushing's disease and hypercortisolism.
• Xeris Biopharma Holdings, Inc.: Markets Recorlev (levoketoconazole) for hypercortisolism.
• Teva Pharmaceuticals USA, Inc.: Launched a generic version of Korlym in January 2024.
• Off-label treatments: Generic ketoconazole and metyrapone are prescribed off-label for hypercortisolism.

Emerging Competitive Threats: The primary emerging threat is the continued availability and potential success of generic versions of Korlym, which could reduce Corcept Therapeutics Incorporated's revenue.

Competitive Response Strategy: Corcept Therapeutics Incorporated has launched its own authorized generic version of Korlym. The Company is actively developing next-generation selective cortisol modulators, such as relacorilant, designed to offer improved safety profiles by avoiding PR affinity, hypokalemia, and QT prolongation, aiming to differentiate from existing and generic treatments. Corcept Therapeutics Incorporated also vigorously defends its intellectual property rights through litigation, although an appeal regarding Korlym patents against Teva Pharmaceuticals USA, Inc. was unsuccessful.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Generic Competition: The availability of generic versions of Korlym, including from Teva Pharmaceuticals USA, Inc., could adversely affect revenue and financial position.
• Public Perception of Mifepristone: Mifepristone's association with pregnancy termination, especially in the context of the Dobbs v. Jackson Women’s Health Organization decision and potential re-examination by the HHS, could lead to restrictions on distribution or negative public attention, limiting sales of Korlym.
• Healthcare Reform & Reimbursement: New laws and regulations, such as the Inflation Reduction Act of 2022 (IRA) and the One Big Beautiful Bill Act of 2025 (OBBBA), could impose price controls, reduce Medicare/Medicaid reimbursement rates, and increase costs for patient assistance programs, negatively impacting profitability.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Vendor Dependency: Reliance on contract manufacturers for API and finished products, and on specialty pharmacy vendors (Curant Health Georgia, LLC) for distribution, creates dependency risks. Failure of these vendors to perform, meet demand, or comply with cGMP regulations could disrupt supply and clinical trials.
• Geographic Concentration: Headquarters in the earthquake, wildfire, and flooding-prone San Francisco Bay Area, and manufacturing/distribution partners in hurricane/tornado-prone regions, expose operations to natural disaster risks exacerbated by global warming.
• Capacity Constraints: In 2025, the primary specialty pharmacy vendor was unable to fully meet demand for Products, highlighting potential capacity limitations.

Financial & Regulatory Risks

Market & Financial Risks:

• Capital Needs: Potential need for additional capital to fund operations or strategic initiatives, which may not be available on acceptable terms or could lead to dilution or restrictive covenants.
• Stock Price Volatility: The Company's stock price is subject to wide fluctuations due to operating results, clinical trial outcomes, regulatory approvals, intellectual property disputes, and broader market conditions.
• Short Selling: Exposure to short selling strategies that may drive down stock price and increase volatility.

Regulatory & Compliance Risks:

• Regulatory Approval Uncertainty: Clinical drug development is lengthy, expensive, and uncertain. The FDA's Complete Response Letter for relacorilant for hypercortisolism indicates that regulatory approval is not guaranteed, even with positive trial results.
• Undesirable Side Effects: Products or product candidates may cause unforeseen or severe adverse events, leading to halted development, denied approval, commercial limitations, or significant liability.
• Marketing & Fraud Laws: Risk of civil or criminal penalties if marketing practices violate FDA regulations (e.g., off-label promotion) or federal/state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA). The Company is currently cooperating with a records subpoena from the United States Attorney’s Office for the District of New Jersey regarding Korlym sales and promotion.
• Data Privacy & Security: Subject to evolving and stringent federal, state, and foreign data privacy laws (e.g., HIPAA, CCPA, GDPR, Bulk Transfer Rule), with non-compliance potentially leading to significant fines, litigation, and reputational harm.
• Legal Proceedings: Involved in a purported securities class action related to relacorilant's NDA, ongoing antitrust litigation concerning specialty pharmacy services, and patent litigation regarding Korlym (unsuccessful appeal against Teva Pharmaceuticals USA, Inc.).

Geopolitical & External Risks

Geopolitical Exposure:

• Government Actions: Actions by the U.S. federal government, including funding reductions for scientific research, staffing disruptions at regulatory agencies (e.g., FDA shutdowns), and changes in trade policies (tariffs), create economic and regulatory uncertainty.
• Trade Relations: Imposition or changes in tariffs on international trade could increase costs for materials and products.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Corcept Therapeutics Incorporated's R&D is centered on modulating the effects of cortisol, specifically through the discovery and development of selective cortisol modulators that bind potently to the glucocorticoid receptor (GR) but lack affinity for the progesterone receptor (PR). This approach aims to avoid PR-related side effects associated with non-selective modulators like mifepristone. The Company has a portfolio of over 1,000 such proprietary compounds across four structurally distinct series. Innovation Pipeline:

• Relacorilant: Lead compound in clinical trials for hypercortisolism (NDA submitted, CRL received), platinum-resistant ovarian cancer (NDA/MAA submitted), platinum-sensitive ovarian cancer, endometrial cancer, and pancreatic cancer.
• Nenocorilant: In Phase 1b clinical trials for solid tumors in combination with immunotherapy.
• Miricorilant: In Phase 2b clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
• Dazucorilant: In Phase 2 clinical trials for amyotrophic lateral sclerosis (ALS), with a pivotal Phase 3 trial expected to start in 2026.
• Early-Stage Development: Continues to create new selective cortisol modulators and advance promising candidates toward clinical development.

Intellectual Property Portfolio:

• Patent Strategy: Corcept Therapeutics Incorporated owns U.S. composition of matter patents for its next-generation cortisol modulators, with expiration dates ranging from 2028 to 2042. Foreign counterparts exist in Europe, Japan, China, Canada, and Australia. The Company also holds U.S. method of use patents for Korlym (expiring 2028-2038) and for its proprietary selective cortisol modulators in hypercortisolism (expiring 2033-2040), various cancers (expiring 2033-2042), ALS, fatty liver disease (MASH), catatonia, psychosis, migraine headaches, and combined steroid/GR modulator therapy (expiring 2026-2043).
• Licensing Programs: Exclusively licensed U.S. patents from the University of Chicago for the use of cortisol modulators in triple-negative breast cancer and castration-resistant prostate cancer, requiring customary milestone fees and royalties on commercialized products.
• IP Litigation: Corcept Therapeutics Incorporated was involved in patent infringement litigation against Teva Pharmaceuticals USA, Inc. regarding Korlym patents, where the appellate court affirmed a ruling of no infringement on February 19, 2026.

Technology Partnerships:

• University of Chicago: Collaborates on a randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer.
• ARCAGY-GINECO: Collaborating to initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with cervical cancer in the first quarter of 2026.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Corcept Therapeutics Incorporated acknowledges the intensely competitive job market for qualified personnel and the risk of losing key managerial, scientific, sales, marketing, and financial staff, which could delay research, development, and commercialization efforts. The Company does not have employment insurance covering any of its personnel.

Board Composition: The Board of Directors includes James N. Wilson (Chairman), Gregg Alton, G. Leonard Baker, Jr., David L. Mahoney, Joshua Murray, Kimberly Park, and Daniel N. Swisher, Jr. The Audit Committee of the Board of Directors oversees cybersecurity.

Human Capital Strategy

Workforce Composition:

• Total Employees: 730 employees as of December 31, 2025.
• Geographic Distribution: Not explicitly detailed in the filing.
• Skill Mix: Not explicitly detailed in the filing.

Talent Management: Acquisition & Retention: Corcept Therapeutics Incorporated aims to hire, retain, and motivate smart, ethical, hard-working employees, officers, and directors. The Company offers a collegial work environment that encourages creativity, collaboration, and initiative. Compensation includes competitive salaries, performance bonuses, equity grants, and industry-leading health, retirement, and other benefits.

• Retention Metrics: Not explicitly detailed in the filing.
• Employee Value Proposition: Focuses on competitive compensation, comprehensive benefits, and a supportive work culture.

Diversity & Development: Not explicitly detailed in the filing. Culture & Engagement: Fosters a collegial work environment that encourages creativity, collaboration, and initiative.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Corcept Therapeutics Incorporated acknowledges that all its activities, as well as those of its vendors, consultants, clinical investigators, patients, physicians, and regulators, are subject to the risks posed by global warming. No specific emissions targets, carbon neutrality commitments, or renewable energy adoption strategies are explicitly detailed in the filing. Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives:

• Community Investment: Corcept Therapeutics Incorporated donates money to independent charitable foundations that assist financially needy patients with the costs associated with their hypercortisolism care.
• Product Impact: The Company maintains a policy that no patient will be denied access to its Products due to inability to pay, offering patient support programs and providing Products at no cost to uninsured patients who do not qualify for charitable support.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing.
• Economic Sensitivity: The Company's business is sensitive to changes in federal government funding for healthcare programs, such as Medicaid. The One Big Beautiful Bill Act, enacted in July 2025, significantly reduced Medicaid funding, which is expected to increase the cost of Corcept Therapeutics Incorporated's financial assistance and charitable donation programs.
• Industry Cycles: Not explicitly detailed in the filing.

Planning & Forecasting: Revenue forecasting is complex, dependent on sales and marketing efficacy, pricing from private and government payers, competition (including generics), and changes in government regulations. These factors are difficult to predict, leading to potential variations between actual revenue and public guidance.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Corcept Therapeutics Incorporated operates under extensive pre- and post-approval regulations from the FDA, EMA, and comparable foreign regulatory authorities. This includes requirements for research, development, testing, manufacturing (cGMP), quality control, clinical trials (GCP), labeling, packaging, distribution, adverse event reporting, advertising, promotion, and marketing. The Company's products and candidates are subject to the Federal Food, Drug and Cosmetic Act, Hatch-Waxman Amendments, Orphan Drug Act, and Fast Track designation provisions. International Compliance: Marketing approval and pricing approval are required in most countries outside the United States, with varying procedures and timelines. Trade & Export Controls: The U.S. Department of Justice's "Bulk Transfer Rule" (28 CFR part 202), issued in 2025, prohibits and restricts bulk transfers of sensitive personal data (including genetic and health data) to "countries of concern," which may increase compliance costs and impact cross-border transactions involving genomic or biological samples and related data.

Legal Proceedings:

• Purported Securities Class Action: A complaint was filed on February 20, 2026, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, claiming false and misleading statements regarding the relacorilant NDA for hypercortisolism. Corcept Therapeutics Incorporated intends to vigorously defend against this lawsuit.
• Teva Patent Litigation: On February 19, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a District Court ruling that Teva Pharmaceuticals USA, Inc.'s generic version of Korlym would not infringe Corcept Therapeutics Incorporated's patents.
• Antitrust Litigation: Teva Pharmaceuticals USA, Inc. filed a complaint on June 13, 2024, alleging antitrust and unfair business practices against Corcept Therapeutics Incorporated and Optime Care, Inc. A trial is scheduled for March 2027. A similar lawsuit was filed by Aetna Inc., Health Care Service Corporation, Humana Inc., and Molina Healthcare Inc. on February 10, 2025, which has been remanded to state court.
• November 2021 Records Subpoena: Corcept Therapeutics Incorporated received a subpoena from the United States Attorney’s Office for the District of New Jersey in November 2021, seeking documents related to the sale and promotion of Korlym, relationships with healthcare professionals, and prior authorizations/reimbursement. Corcept Therapeutics Incorporated is cooperating with the investigation and is not currently considered a defendant.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The effective income tax rate for the year ended December 31, 2025, was (50.0)%, differing from the U.S. federal statutory rate of 21.0%. Key drivers of this difference included state and local income tax (net of federal benefit) of (2.9)%, research and development credits of (22.2)%, stock-based compensation of (61.9)%, and non-deductible executive compensation of 12.8%.
• Geographic Tax Planning: Income before income taxes for 2025 was $62.9 million domestically and $3.6 million from foreign operations.
• Tax Reform Impact: The One Big Beautiful Bill Act, enacted July 4, 2025, allows for immediate expensing of domestic U.S. research and development expenses and certain capital expenditures, and includes other changes to the U.S. taxation of foreign profits, materially reducing current income taxes payable and deferred tax asset balances in fiscal year 2025. The 15% corporate alternative minimum tax on adjusted financial statement income became effective January 1, 2024, but is not expected to significantly affect consolidated financial statements.

Net Operating Loss Carryforwards: As of December 31, 2025, Corcept Therapeutics Incorporated had federal net operating loss carryforwards of $397.8 million (do not expire), California net operating loss carryforwards of $63.3 million (begin to expire in 2033), and other state net operating loss carryforwards of $119.2 million (expire at various future dates).

Research and Development Tax Credits: As of December 31, 2025, the Company had federal research and development tax credits of $18.4 million (begin to expire in 2045) and California research and development tax credits of $25.2 million (no expiration date).

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Corcept Therapeutics Incorporated's insurance, if available, would likely be insufficient to cover losses resulting from disasters or other business interruptions. No specific details on policy types, coverage limits, or self-insurance retention are provided.
• Risk Transfer Mechanisms: Not explicitly detailed in the filing.